NCT06116903 Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes
| NCT ID | NCT06116903 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Limoges |
| Condition | Glioma |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-04-11 |
| Primary Completion | 2025-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-04-11 with a primary completion date of 2025-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this pilot study is that exosomes constitute a more interesting support for analyzes allowing a broader screening of molecular alterations to be carried out with more reliable, more sensitive and more efficient results than the reference Foundation One Liquid CDx test.
Eligibility Criteria
Inclusion Criteria: * Subject of both sexes at least 18 years of age with glioblastoma. * Patient for whom an FMI test is indicated, progressing after a 1st line following the chemotherapy and radiotherapy protocol (STUPP protocol) * Patient affiliated to French social security Exclusion Criteria: * Patient included in another research protocol using an experimental molecule. * Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the patient from adhering to the protocol or completing the study per protocol * Patient under legal protection, guardianship or curatorship * Patient with active malignancy or a previous malignancy within the past 5 years; except for patient with resected Basocarcinoma and resected carcinoma in-situ of the cervix.
Frequently Asked Questions
Who can join the NCT06116903 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06116903 currently recruiting?
Yes, NCT06116903 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Hospital, Limoges to inquire about joining.
Where is the NCT06116903 trial being conducted?
This trial is being conducted at Limoges, France.
Who is sponsoring the NCT06116903 clinical trial?
NCT06116903 is sponsored by University Hospital, Limoges. The trial plans to enroll 60 participants.